Sales came in slightly below our expectations, while EBIT exceeded both our estimates and consensus. Organic growth remained strong, supported by improved deliveries in Surgical Instruments, while Surgical Tables maintained solid momentum. We leave our estimates unchanged but update our Fair Value to SEK296 per share.
